Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Reponds to recent market speculation regarding a possible fundraising. Says no fundraising is imminent. Notes it has a strong cash balance of £27 million as at May 31 and expects strong new flow in the company months.

Current stock price: 104.75 pence, up 5.8% in London on Monday afternoon

12-month change: more than tripled from 28.99p

Copyright 2023 Alliance News Ltd. All Rights Reserved.